Dabrafenib (GSK2118436)

Catalog No.S2807

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Cited by 135 Publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )
Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )
Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )
ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )
Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )
Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	NYXJXoxiU2mwYYPlJGF{e2G7				NF:zbFdKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{KHSjZ3fl[EBDNVKjZjDWOlAxTSCvdYThcpQh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDj[YxteyClbz3lfJBz\XO\|aX7nJGNFSzN5IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGKrb4Tpcplt[XSnZD3NSWsheHKxdHXpckBxcG:\|cHjvdplt[XSrb36gZpkhSWyyaHHTZ5Jm\W5iYYPzZZkhf2m2aDDJR\|UxKG:oIECuNFAxPyEQvF2=	NWrGWZoyOjR7MEC2O\|M>
SK-MEL-28	MWHLbY5ie2ViQYPzZZk>		NF3pcnYyKGh?		M37VTGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2=	NFrXeZIzPDlyME[3Ny=>
HepG2	MWfLbY5ie2ViQYPzZZk>				M{PGZWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>?	MnzmNlQ6ODB4N{O=
COLO205	NYPEdJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nSPGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR\|UxKG:oIECuNFA4KM7:TR?=	MW[yOFkxODZ5Mx?=
HepG2	M4rnOWZ2dmO2aX;uJGF{e2G7		NGfK[4g1PSCvaX6=	M4[0VGROW09?	Mn3oTY5pcWKrdHnvckBw\iCDbHu1JIlvKFSJRj3i[ZRiNXO2aX31cIF1\WRiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hW22jZEKgdIhwe3Cqb4L5cIF1cW:wIITy[YF1\WRiZn;yJFQ2KG2rboOgdJJqd3JidH:gWGdHNWKndHGgd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgOlAhdWmwczDifUBw\Hm\|c3X5JIJtd3Ric3Phco5meiCjbnHsfZNqeyC5aYToJGlEPTBib3[gN{44KM7:TR?=	NX7nRpVGOjR7MEC2O\|M>
HFF	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOxNEDPxE1?	NGHIOGM4OiCq	NVLQPHVXTE2VTx?=	M3LycmlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0>	NHfzS2czOzh2NECzPC=>
SK-MEL-28	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXO3dWdVOTBizszN	M334TVczKGh?	NYHId5VyTE2VTx?=	M{XadGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0>	NWHuWnRuOjN6NESwN\|g>
A375P-F11	M4WyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfiVlZEOTBizszN	MmjkO\|IhcA>?	M131XmROW09?	NFK3bIFKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO	NYHR[nNbOjN6NESwN\|g>
MALME-3M	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoT0NVAh\|ryP	NVHWZZplPzJiaB?=	MVzEUXNQ	NVTiXJBrUUN3ME2xJI5O	MW[yN\|g1PDB\|OB?=
UACC-62	M4\yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL6fmJFOTBizszN	MYm3NkBp	MkW1SG1UVw>?	NVjYc45xUUN3ME2xJI5O	MlHZNlM5PDRyM{i=
C32TG	NVrKNGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[xNEDPxE1?	MYG3NkBp	M{\6OWROW09?	M1myXmlEPTB;MTDuUS=>	NYLiXHJzOjN6NESwN\|g>
SK-MEL-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	NELT[3U4OiCq	NHfsRZVFVVOR	M3nzPGlEPTB;MjDuUS=>	NXG2PIcxOjN6NESwN\|g>
M14	NHz3UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXy[2wyOCEQvF2=	MmnrO\|IhcA>?	M{[zZ2ROW09?	NXHPcWg6UUN3ME2yJI5O	NHL5fJIzOzh2NECzPC=>
SK-MEL-28	NEfOXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVGxNEDPxE1?	MY[3NkBp	MojwSG1UVw>?	NXzlN49FUUN3ME2zJI5O	NEf2TpYzOzh2NECzPC=>
A375	M4XPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUexNEDPxE1?	NHPTeno4OiCq	MlPhSG1UVw>?	MUnJR\|UxRTRibl2=	Mn3nNlM5PDRyM{i=
DU-4475	M4jhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrZNVAh\|ryP	NEO5flk4OiCq	M13qVGROW09?	MnnRTWM2OD13IH7N	MXSyN\|g1PDB\|OB?=
UACC-257	NVjYdWoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzuWIMzOTBizszN	NYPBcYFWPzJiaB?=	MUHEUXNQ	NH[3cIdKSzVyPU[gcm0>	NULSPVdjOjN6NESwN\|g>
Colo 205	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XiWVExKM7:TR?=	MnjLO\|IhcA>?	NFLYRVZFVVOR	MnzjTWM2OD15IH7N	NVTGNFFEOjN6NESwN\|g>
SK-MEL-3	M{\0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H6RVExKM7:TR?=	NFvPfoM4OiCq	NG\2fZpFVVOR	NF7FNFBKSzVyPUegcm0>	NVfXNXhKOjN6NESwN\|g>
SH-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\oe\|lbOTBizszN	NF;pW5E4OiCq	NEDqXZJFVVOR	MWLJR\|UxRThibl2=	MoLnNlM5PDRyM{i=
A101D	NViyTIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;KcIYyOCEQvF2=	Mn7iO\|IhcA>?	MonYSG1UVw>?	MYPJR\|UxRTlibl2=	NYW4THA4OjN6NESwN\|g>
ES-2	NXzJV29LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rNdVExKM7:TR?=	MUm3NkBp	MoH3SG1UVw>?	NXjzT4RwUUN3ME21N{BvVQ>?	M1PvS\|I{QDR2MEO4
HT-29	NVvjZoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXyxNEDPxE1?	MmHPO\|IhcA>?	MYfEUXNQ	MoHQTWM2OD14NjDuUS=>	NWXuWXE5OjN6NESwN\|g>
SW1417	M2TUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[yNVAh\|ryP	MofVO\|IhcA>?	NGrZWnVFVVOR	MX7JR\|UxRTF3ODDuUS=>	M2Tve\|I{QDR2MEO4
SW872	NXHHT48zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXoWI4yOCEQvF2=	MnLWO\|IhcA>?	MkHISG1UVw>?	NVzlU2hrUUN3ME2zO\|chdk1?	NEe5WG8zOzh2NECzPC=>
RKO	M{j1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\qdVcyOCEQvF2=	NFPxTng4OiCq	MUfEUXNQ	NWPsSXB2UUN3ME2yMlUzOiEQvF2=	MlL4NlM5PDRyM{i=
A673	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	M2WwcVczKGh?	MlrWSG1UVw>?	NFPXbphKSzVyPUGwJO69VQ>?	M{X1dVI{QDR2MEO4
GCT	M3fMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXmxNEDPxE1?	NGnUbJI4OiCq	Mn;XSG1UVw>?	M{nUOGlEPTB;MUCg{txO	NH3qOWIzOzh2NECzPC=>
WM-115	NH:zSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDuXGlVOTBizszN	MXO3NkBp	M2nzNmROW09?	NWna[GFMUUN3ME21JI5O	MkfWNlM5PDRyM{i=
YUMAC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7zNVAh\|ryP	MlXWO\|IhcA>?	MkjnSG1UVw>?	NUHHUVF2UUN3ME21JI5O	NWTE[oZUOjN6NESwN\|g>
OV-90	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvUOlcyOCEQvF2=	MXG3NkBp	NGGxZ2pFVVOR	MmiyTWM2OD1{OTDuUS=>	MWeyN\|g1PDB\|OB?=
NCI-H508	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPnNVAh\|ryP	MWi3NkBp	MXHEUXNQ	MoLCTWM2OD1zMDFOwG0>	MUmyN\|g1PDB\|OB?=
MDA-MB-231	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGxNEDPxE1?	M1m4eFczKGh?	NY\jVJhoTE2VTx?=	MWPJR\|UxRTFyIN88US=>	MU[yN\|g1PDB\|OB?=
SW756	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK2NlE5OTBizszN	MXm3NkBp	MWTEUXNQ	NYH5RY1zUUN3ME2xNEDPxE1?	MXqyN\|g1PDB\|OB?=
SW-837	NF:yNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTJNVAh\|ryP	NEW4Sos4OiCq	NWrYfnNwTE2VTx?=	MlvnTWM2OD1zMDFOwG0>	M{PldFI{QDR2MEO4
UMUC-3	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPmdY4yOCEQvF2=	NYOwWohEPzJiaB?=	MX;EUXNQ	M3m3PWlEPTB;MUCg{txO	NIjpflQzOzh2NECzPC=>
LS-174T	NX7YSoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HS[\|ExKM7:TR?=	Ml3VO\|IhcA>?	NXfZR2ZvTE2VTx?=	M4PjVmlEPTB;MUCg{txO	NIHuT3ozOzh2NECzPC=>
A549	NHr5TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXMNVAh\|ryP	MVq3NkBp	MlLQSG1UVw>?	MmftTWM2OD1zMDFOwG0>	MkfyNlM5PDRyM{i=
SHP-77	NGnt[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TUZ\|ExKM7:TR?=	MUC3NkBp	NV:wVG1CTE2VTx?=	NXy0PXAzUUN3ME2xNEDPxE1?	NX7HeJRFOjN6NESwN\|g>
SW480	M{\4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;Cc\|kyOTBizszN	NHzRUJM4OiCq	M171PGROW09?	Ml\BTWM2OD1zMDFOwG0>	NGLrU3IzOzh2NECzPC=>
DLD-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO5NVAh\|ryP	NIrrdFg4OiCq	MWTEUXNQ	NXzHVWNRUUN3ME2xNEDPxE1?	M{DB[\|I{QDR2MEO4
HCT-116	NIXJSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrxRZQ3OTBizszN	M{\zVlczKGh?	Mmi4SG1UVw>?	MV\JR\|UxRTFyIN88US=>	NID2[lEzOzh2NECzPC=>
NCI-H747	NWDNU4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NECyXIsyOCEQvF2=	NYryend{PzJiaB?=	NGf6TIdFVVOR	NHixboNKSzVyPUGwJO69VQ>?	Ml7tNlM5PDRyM{i=
T-84	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXmxNEDPxE1?	NXXrbWN6PzJiaB?=	NILTZYhFVVOR	M1HxWmlEPTB;MUCg{txO	MV6yN\|g1PDB\|OB?=
NCI-H460	M3\nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[5NVAh\|ryP	MVe3NkBp	MXLEUXNQ	NWPvR3lMUUN3ME2xNEDPxE1?	MmHnNlM5PDRyM{i=
Calu-6	NIPVSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PHTlExKM7:TR?=	MUi3NkBp	MknlSG1UVw>?	MlznTWM2OD1zMDFOwG0>	NXe2Ull[OjN6NESwN\|g>
HCC-2998	NIPk[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;2fFExKM7:TR?=	MYW3NkBp	MnLoSG1UVw>?	NVWzNHc3UUN3ME2xNEDPxE1?	M1zCXFI{QDR2MEO4
LS1034	NWf4OI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPLbZc3OTBizszN	MkHwO\|IhcA>?	MYXEUXNQ	M3vMe2lEPTB;MUCg{txO	NWHoclB{OjN6NESwN\|g>
CHP-212	NHTDb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3GydlExKM7:TR?=	MoTvO\|IhcA>?	MVvEUXNQ	NWjwUlNVUUN3ME2xNEDPxE1?	M33hS\|I{QDR2MEO4
SK-N-AS	NV;qboY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPCcJAyOCEQvF2=	MUK3NkBp	MYPEUXNQ	NHrGXHhKSzVyPUGwJO69VQ>?	MljPNlM5PDRyM{i=
BFTC-905	M3PaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS5NVAh\|ryP	MYe3NkBp	M1PsfmROW09?	MYjJR\|UxRTFyIN88US=>	MYiyN\|g1PDB\|OB?=
HuT78	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWOxNEDPxE1?	MXm3NkBp	M{nwNWROW09?	MXTJR\|UxRTV{IH7N	NFryfWIzOzh2NECzPC=>
RPMI-8226	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzWUnpmOTBizszN	MYS3NkBp	NUnleGczTE2VTx?=	MkW2TWM2OD1{NkOgcm0>	M2WyXFI{QDR2MEO4
BC-3	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\6V\|ExKM7:TR?=	NIrNb5I4OiCq	MXPEUXNQ	Ml\6TWM2OD1{N{egcm0>	NH;yTXYzOzh2NECzPC=>
ACHN	NUHkXXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fVU\|ExKM7:TR?=	NEfwR484OiCq	NHTaeHZFVVOR	NGnpcGJKSzVyPUK5OEBvVQ>?	NVm0XZNwOjN6NESwN\|g>
JRT3-T35	M{TUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:4PI0yOCEQvF2=	NH;KNG44OiCq	M3HyUGROW09?	NEf3W29KSzVyPUK5OUBvVQ>?	NFLpV3gzOzh2NECzPC=>
SK-MES-1	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHMNVAh\|ryP	NVW1NGhDPzJiaB?=	MX3EUXNQ	MXPJR\|UxRTN{OTDuUS=>	NWrjTZdYOjN6NESwN\|g>
CESS	M2jvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\VUFExKM7:TR?=	MYe3NkBp	MlXTSG1UVw>?	NHzHXWVKSzVyPUS5O{BvVQ>?	M3X5NlI{QDR2MEO4
H4	M371b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXkdo85OTBizszN	MYC3NkBp	MUjEUXNQ	M{TQVGlEPTB;NkG5JI5O	NHm0[nYzOzh2NECzPC=>
BC-1	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUexNEDPxE1?	M2O1PVczKGh?	MofUSG1UVw>?	NX\xN4tuUUN3ME23NFQhdk1?	M325RlI{QDR2MEO4
DB	NH61OIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvwTJQyOCEQvF2=	Mn;wO\|IhcA>?	MWDEUXNQ	MmO5TWM2OD16N{Ogcm0>	NV3RRlVoOjN6NESwN\|g>
RPMI-6666	NGDLSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LMT\|ExKM7:TR?=	NX\5XpVzPzJiaB?=	Mo\QSG1UVw>?	NVW5V\|g4UUN3ME25Nlghdk1?	MVeyN\|g1PDB\|OB?=
MC/CAR	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;5NVAh\|ryP	MlG5O\|IhcA>?	Mlv2SG1UVw>?	MkXjTWM2OD1zLkCwNkDPxE1?	NFjkdogzOzh2NECzPC=>
SNU-1	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\NcJpsOTBizszN	NX70enM1PzJiaB?=	M3v6XWROW09?	MYHJR\|UxRTFwNUCxJO69VQ>?	M1jTW\|I{QDR2MEO4
CEM/C1	NUPtbIt5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvjNVAh\|ryP	MoPSO\|IhcA>?	NXHHSpczTE2VTx?=	NIHIcFFKSzVyPUGuO\|c{KM7:TR?=	M{m0flI{QDR2MEO4
GDM-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3u5ZVExKM7:TR?=	NFH3bmY4OiCq	Ml3RSG1UVw>?	M2\RSWlEPTB;MT65PVch\|ryP	MWWyN\|g1PDB\|OB?=
HT-1080	NYfF[GhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDENVAh\|ryP	MmHCO\|IhcA>?	NW\jTFhvTE2VTx?=	NEHYTnlKSzVyPUKuNFA1KM7:TR?=	NUjlR5Z[OjN6NESwN\|g>
HL-60	M2nFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGn5UZgyOCEQvF2=	M{jHPVczKGh?	NU\JTFJHTE2VTx?=	M2O0UWlEPTB;Mj6xO\|gh\|ryP	NH7SRZkzOzh2NECzPC=>
C3A	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr5TGdWOTBizszN	NIHGOIw4OiCq	NUfPTlBWTE2VTx?=	MnzRTWM2OD13LkSxOEDPxE1?	NGnObWUzOzh2NECzPC=>
MES-SA	NYmwcm9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTLNVAh\|ryP	MXS3NkBp	NVPrPYhGTE2VTx?=	M3nyOmlEPTB;Nj65PFkh\|ryP	M2jONVI{QDR2MEO4
22Rv1	NGfxclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWOyRphqOTBizszN	NWfHUldZPzJiaB?=	Mn3LSG1UVw>?	M1\DeWlEPTB;MUCg{txO	NFrtPWEzOzh2NECzPC=>
647-V	M1n4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XIe\|ExKM7:TR?=	NIXENVE4OiCq	Ml;SSG1UVw>?	NXiwO\|E1UUN3ME2xNEDPxE1?	NX\WeI5LOjN6NESwN\|g>
786-O	NHL0TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvvNVAh\|ryP	M4TB[lczKGh?	MnPYSG1UVw>?	MmPtTWM2OD1zMDFOwG0>	M{XaN\|I{QDR2MEO4
A172	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrscWg3OTBizszN	M1jDOlczKGh?	NE\hVYVFVVOR	NHTXVJVKSzVyPUGwJO69VQ>?	MXeyN\|g1PDB\|OB?=
A204	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7LN\|BCOTBizszN	NHfEZXc4OiCq	MlTXSG1UVw>?	MkHrTWM2OD1zMDFOwG0>	NUHaWIlIOjN6NESwN\|g>
A427	M2\jZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHwNVAh\|ryP	NX7tO3p4PzJiaB?=	M3jabGROW09?	NFu4enZKSzVyPUGwJO69VQ>?	MkjUNlM5PDRyM{i=
A431	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[3NVAh\|ryP	NGDNcYs4OiCq	MWXEUXNQ	MnH1TWM2OD1zMDFOwG0>	M{C2blI{QDR2MEO4
A2780	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jublExKM7:TR?=	NFLVZ404OiCq	M{LLWWROW09?	MWrJR\|UxRTFyIN88US=>	NVzkW2pQOjN6NESwN\|g>
ARH-77	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn25NVAh\|ryP	NHvRZ\|c4OiCq	MYjEUXNQ	NV6wZXpJUUN3ME2xNEDPxE1?	M2DYfFI{QDR2MEO4
Be(2)C	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUGxNEDPxE1?	M2iwVVczKGh?	MUjEUXNQ	NXq3NXF6UUN3ME2xNEDPxE1?	MoXkNlM5PDRyM{i=
BT-20	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv3T4tSOTBizszN	MUC3NkBp	MWTEUXNQ	NY\hOo1jUUN3ME2xNEDPxE1?	NHvIdIkzOzh2NECzPC=>
BxPc3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLqNVAh\|ryP	NFzzNIM4OiCq	M2\wWGROW09?	MnHPTWM2OD1zMDFOwG0>	NWDyRpV1OjN6NESwN\|g>
C-4 I	NEXaWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoX1NVAh\|ryP	NXXhe3FVPzJiaB?=	MkjsSG1UVw>?	M2jIPGlEPTB;MUCg{txO	NYTQR\|Y4OjN6NESwN\|g>
C33A	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXaRYkyOCEQvF2=	MkixO\|IhcA>?	NULReFNnTE2VTx?=	MlHiTWM2OD1zMDFOwG0>	M1WzT\|I{QDR2MEO4
CAL-27	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1L4eFExKM7:TR?=	MXe3NkBp	M1Gz[mROW09?	MnywTWM2OD1zMDFOwG0>	MmjzNlM5PDRyM{i=
CAL-62	NEfNc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETvSJEyOCEQvF2=	MUS3NkBp	MV7EUXNQ	M1qyWWlEPTB;MUCg{txO	NFvjZokzOzh2NECzPC=>
Calu-3	NYDuRoxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XxclExKM7:TR?=	MkKxO\|IhcA>?	M4DhVmROW09?	MU\JR\|UxRTFyIN88US=>	MX2yN\|g1PDB\|OB?=
CaOV3	NYLHRphRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnJNVAh\|ryP	Mn7DO\|IhcA>?	Mn;XSG1UVw>?	MnPPTWM2OD1zMDFOwG0>	MnrwNlM5PDRyM{i=
CGTHW1	NUTV[\|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jyVlExKM7:TR?=	M2LFSlczKGh?	MnnLSG1UVw>?	M2e3SmlEPTB;MUCg{txO	MlPmNlM5PDRyM{i=
CHL-1	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PhSlExKM7:TR?=	MUS3NkBp	NIHaSmNFVVOR	MVzJR\|UxRTFyIN88US=>	NHzxVoEzOzh2NECzPC=>
Colo320DM	NHntNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHMXJAyOCEQvF2=	NGXBUI84OiCq	M{LZRmROW09?	NFzzNINKSzVyPUGwJO69VQ>?	M4nhOlI{QDR2MEO4
Colo704	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnie5oyOCEQvF2=	NHf5[GY4OiCq	NYTQV49GTE2VTx?=	NVLpVo9iUUN3ME2xNEDPxE1?	NGm4SJIzOzh2NECzPC=>
COR-L23	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\hNVAh\|ryP	NGLsWZk4OiCq	M3z3SWROW09?	MXPJR\|UxRTFyIN88US=>	Mlq2NlM5PDRyM{i=
CRO-AP2	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixNEDPxE1?	M{XsTVczKGh?	NXrhO4FQTE2VTx?=	Mn\1TWM2OD1zMDFOwG0>	MVyyN\|g1PDB\|OB?=
Daudi	M1vm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHGW48yOCEQvF2=	M2fmXFczKGh?	MnnHSG1UVw>?	MWTJR\|UxRTFyIN88US=>	M4nOdFI{QDR2MEO4
DOTC 24510	M1TmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCxNEDPxE1?	NXj6O5Q4PzJiaB?=	M2LMcGROW09?	NHXuXYNKSzVyPUGwJO69VQ>?	M3LxNVI{QDR2MEO4
DU-145	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfwNVAh\|ryP	MoLBO\|IhcA>?	M{PjNGROW09?	NXPIZll[UUN3ME2xNEDPxE1?	MnWwNlM5PDRyM{i=
EB-3	NI\lfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PNc\|ExKM7:TR?=	NVHveW9MPzJiaB?=	NUnBRlZrTE2VTx?=	M3znU2lEPTB;MUCg{txO	NVPnXmtiOjN6NESwN\|g>
EFM-19	M1zibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nuTVExKM7:TR?=	MlS5O\|IhcA>?	M1n5NmROW09?	M1LTemlEPTB;MUCg{txO	M3TOdlI{QDR2MEO4
EKVX	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HiNFExKM7:TR?=	NVvnVmhYPzJiaB?=	NFT4TVNFVVOR	M{XncGlEPTB;MUCg{txO	NIjY[nMzOzh2NECzPC=>
FaDu	M4Dhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUexNEDPxE1?	M3vGTVczKGh?	NVrqfVVWTE2VTx?=	MY\JR\|UxRTFyIN88US=>	Ml7lNlM5PDRyM{i=
G401	NFrTRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPYNVAh\|ryP	M2K3fFczKGh?	M1nMRWROW09?	MV3JR\|UxRTFyIN88US=>	M4\wT\|I{QDR2MEO4
HCC-70	NUO1OoNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[xNEDPxE1?	NUPTNVV3PzJiaB?=	NEm1dGRFVVOR	NH7XW5RKSzVyPUGwJO69VQ>?	M17QclI{QDR2MEO4
HCC-1954	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rsflExKM7:TR?=	NF[5c3c4OiCq	MoW5SG1UVw>?	M{HPTWlEPTB;MUCg{txO	MoC3NlM5PDRyM{i=
Hela	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\2SXJFOTBizszN	NXrIfoNXPzJiaB?=	MVPEUXNQ	NIPW[YxKSzVyPUGwJO69VQ>?	M1nV[lI{QDR2MEO4
Hep3B	NFq4TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHXNVAh\|ryP	NV\mOlZyPzJiaB?=	MlPzSG1UVw>?	MWTJR\|UxRTFyIN88US=>	NEWyTGozOzh2NECzPC=>
HMCB	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XreVExKM7:TR?=	M3fNSFczKGh?	M{C4TWROW09?	MkXSTWM2OD1zMDFOwG0>	NVrUTVQ{OjN6NESwN\|g>
HN5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\NNVAh\|ryP	MoHXO\|IhcA>?	NXvMZ4tpTE2VTx?=	NXLOXY9rUUN3ME2xNEDPxE1?	MVeyN\|g1PDB\|OB?=
HOS	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnE[4E1OTBizszN	NWPodpdQPzJiaB?=	M1jDVGROW09?	NYKyUZhqUUN3ME2xNEDPxE1?	NYnCNmp[OjN6NESwN\|g>
HPAF-II	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHexRnoyOCEQvF2=	Mn;6O\|IhcA>?	MoTjSG1UVw>?	MWfJR\|UxRTFyIN88US=>	NYPN[GJHOjN6NESwN\|g>
Hs746.T	NX7pUoJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxNEDPxE1?	MoLkO\|IhcA>?	MnLzSG1UVw>?	MX\JR\|UxRTFyIN88US=>	MUWyN\|g1PDB\|OB?=
HT	NX\wSJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[yO5A{OTBizszN	M3TuSlczKGh?	MV\EUXNQ	MkTjTWM2OD1zMDFOwG0>	MXeyN\|g1PDB\|OB?=
HT-3	M{C5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrhNVAh\|ryP	NGLFdIo4OiCq	MoXzSG1UVw>?	NVPRXmtMUUN3ME2xNEDPxE1?	MkjMNlM5PDRyM{i=
HuNS-1	M375NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUSxNEDPxE1?	NXvlTJp2PzJiaB?=	M{PQXmROW09?	NIfm[JVKSzVyPUGwJO69VQ>?	Ml\QNlM5PDRyM{i=
IGROV1	NWHTfmVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrsNVAh\|ryP	NHPxSFM4OiCq	M3jNfmROW09?	Ml3yTWM2OD1zMDFOwG0>	MWSyN\|g1PDB\|OB?=
J82	NX;vR5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fy[\|ExKM7:TR?=	MmT2O\|IhcA>?	M33MUWROW09?	MYXJR\|UxRTFyIN88US=>	NYj1NYhYOjN6NESwN\|g>
JM1	NVLNdItiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCxNEDPxE1?	NIT2R2Q4OiCq	NGS4ZlNFVVOR	M2jM[GlEPTB;MUCg{txO	M3zidFI{QDR2MEO4
Kato III	NG\Qd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjJXGJZOTBizszN	Mnf2O\|IhcA>?	NWj1OWhZTE2VTx?=	NGXxc5NKSzVyPUGwJO69VQ>?	NFXpfo4zOzh2NECzPC=>
KHOS-240S	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;J[JkyOCEQvF2=	MlvkO\|IhcA>?	MVPEUXNQ	MULJR\|UxRTFyIN88US=>	NEjSUXczOzh2NECzPC=>
KM-12	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxNEDPxE1?	NH31UmI4OiCq	M2n3WGROW09?	MX;JR\|UxRTFyIN88US=>	NX;vNXRwOjN6NESwN\|g>
KPL-1	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{mzbVExKM7:TR?=	MoX2O\|IhcA>?	MWHEUXNQ	M3\V[GlEPTB;MUCg{txO	M2W1[lI{QDR2MEO4
KYSE-30	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj3WY8yOCEQvF2=	M4KzS\|czKGh?	NIrnOGZFVVOR	NIfRXodKSzVyPUGwJO69VQ>?	MU[yN\|g1PDB\|OB?=
LNCaP	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXjTGNSOTBizszN	MX63NkBp	MlrPSG1UVw>?	NWTYNJd[UUN3ME2xNEDPxE1?	MmTjNlM5PDRyM{i=
MCF-7	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPNOlIyOCEQvF2=	NIPzOWk4OiCq	MWLEUXNQ	M3v2b2lEPTB;MUCg{txO	MkWwNlM5PDRyM{i=
MC-IXC	NEDNZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojjNVAh\|ryP	MWe3NkBp	MVzEUXNQ	NYCzcYN3UUN3ME2xNEDPxE1?	MoPINlM5PDRyM{i=
MDA-MB-175 VII	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlewNVAh\|ryP	NVW1bpZ7PzJiaB?=	MUPEUXNQ	MoL0TWM2OD1zMDFOwG0>	MlXnNlM5PDRyM{i=
MDA-MB-468	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPGfGkyOCEQvF2=	M3;ufVczKGh?	MUTEUXNQ	MYLJR\|UxRTFyIN88US=>	NIP3NIgzOzh2NECzPC=>
MiaPaCa	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYqxNEDPxE1?	MV:3NkBp	NETUXVVFVVOR	M{\XXGlEPTB;MUCg{txO	M4nIdVI{QDR2MEO4
Molt-4	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7iNVAh\|ryP	NF31eHM4OiCq	NIT0XW1FVVOR	NWPhN5IzUUN3ME2xNEDPxE1?	Mk[yNlM5PDRyM{i=
NCI-ADR/RES	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G3V\|ExKM7:TR?=	M4DYOlczKGh?	NIK3eZZFVVOR	MlvtTWM2OD1zMDFOwG0>	Mnv1NlM5PDRyM{i=
NCI-H69	NXfOT5piT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHiWG0yOCEQvF2=	NXrqRoF7PzJiaB?=	NFrQ[opFVVOR	M2Dq[WlEPTB;MUCg{txO	Mm\YNlM5PDRyM{i=
NCI-H82	NULQeYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOxNEDPxE1?	NFfRVHc4OiCq	NFW3TJVFVVOR	NICxPXJKSzVyPUGwJO69VQ>?	NV3odmpZOjN6NESwN\|g>
NCI-N87	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mly2NVAh\|ryP	NUXXTlNmPzJiaB?=	MV3EUXNQ	NVjWR5ZbUUN3ME2xNEDPxE1?	MmSwNlM5PDRyM{i=
NCI-H146	NHzjdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfqd5UyOCEQvF2=	MWK3NkBp	Mk\0SG1UVw>?	M1\vVGlEPTB;MUCg{txO	M{jIZ\|I{QDR2MEO4
NCI-H157	MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnn5NVAh\|ryP	MVu3NkBp	MoHiSG1UVw>?	Mn61TWM2OD1zMDFOwG0>	MljXNlM5PDRyM{i=
NCI-H187	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPreVkyOCEQvF2=	NYH2coNCPzJiaB?=	M130WWROW09?	NILuPHBKSzVyPUGwJO69VQ>?	M{SySlI{QDR2MEO4
NCI-H209	M{K3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYmxNEDPxE1?	NY\2[YNuPzJiaB?=	NHjWPYRFVVOR	NY\H[IZDUUN3ME2xNEDPxE1?	NXrN[IJuOjN6NESwN\|g>
NCI-H226	NI\FdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljJNVAh\|ryP	MWS3NkBp	MYHEUXNQ	NF7DW4NKSzVyPUGwJO69VQ>?	NX7Ib29EOjN6NESwN\|g>
NCI-H292	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv2NVAh\|ryP	NXKyToxsPzJiaB?=	NYXjbGdRTE2VTx?=	Mk\1TWM2OD1zMDFOwG0>	MnLDNlM5PDRyM{i=
NCI-H322	NV;ROlhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M163UVExKM7:TR?=	MYm3NkBp	NFXIRldFVVOR	NIDKXY1KSzVyPUGwJO69VQ>?	NH;SUpIzOzh2NECzPC=>
NCI-H358	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;4VIVOOTBizszN	M36yW\|czKGh?	NXjSVXJLTE2VTx?=	M{fJNGlEPTB;MUCg{txO	M4PDNFI{QDR2MEO4
NCI-H520	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof4NVAh\|ryP	NYjTZ3p7PzJiaB?=	NUS3OnB1TE2VTx?=	MWPJR\|UxRTFyIN88US=>	NGTSV\|UzOzh2NECzPC=>
NCI-H526	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNEDPxE1?	NEXLRm04OiCq	MlHZSG1UVw>?	NIfkeGJKSzVyPUGwJO69VQ>?	M1PkXVI{QDR2MEO4
NCI-H630	NEjRU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4H4[lExKM7:TR?=	NHfZTVY4OiCq	NY\xdGtCTE2VTx?=	M4nlUGlEPTB;MUCg{txO	MWeyN\|g1PDB\|OB?=
NCI-H661	NE\5TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVixNEDPxE1?	MU[3NkBp	MWrEUXNQ	Ml;zTWM2OD1zMDFOwG0>	MWGyN\|g1PDB\|OB?=
NCI-H716	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPHZ41nOTBizszN	MnzmO\|IhcA>?	NYjURmNKTE2VTx?=	M1fRd2lEPTB;MUCg{txO	M{XlXlI{QDR2MEO4
NCI-H1563	NHzrRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rEZVExKM7:TR?=	NGPsZXI4OiCq	MXjEUXNQ	Ml7aTWM2OD1zMDFOwG0>	NX7v[HJNOjN6NESwN\|g>
NCI-H1792	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TaZlExKM7:TR?=	NIfEWIM4OiCq	MkfSSG1UVw>?	M2mxdmlEPTB;MUCg{txO	NWnlRnFWOjN6NESwN\|g>
NCI-H2030	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUWxNEDPxE1?	NVvIOoE2PzJiaB?=	MkXOSG1UVw>?	M3y1TWlEPTB;MUCg{txO	M4ToblI{QDR2MEO4
NCI-H2052	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HK[FExKM7:TR?=	Mnq0O\|IhcA>?	MX;EUXNQ	Ml;KTWM2OD1zMDFOwG0>	MWmyN\|g1PDB\|OB?=
NCI-H2122	NGrmd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfxVVV3OTBizszN	M1\vWVczKGh?	MVfEUXNQ	NFzpcotKSzVyPUGwJO69VQ>?	MVuyN\|g1PDB\|OB?=
NCI-H2228	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nDU\|ExKM7:TR?=	MWW3NkBp	NWLEenkyTE2VTx?=	M1jRcWlEPTB;MUCg{txO	NFm4N3QzOzh2NECzPC=>
OE-19	NGXFNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[xNEDPxE1?	NULm[JVNPzJiaB?=	MVnEUXNQ	MWXJR\|UxRTFyIN88US=>	NWDsOpRKOjN6NESwN\|g>
OE-21	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojXNVAh\|ryP	MU[3NkBp	M3jaXGROW09?	MWjJR\|UxRTFyIN88US=>	MnnFNlM5PDRyM{i=
OE-33	M2ntVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHGycZUyOCEQvF2=	NHPRNYo4OiCq	NXXpZ4ZPTE2VTx?=	MVvJR\|UxRTFyIN88US=>	NHLjVHQzOzh2NECzPC=>
OVCAR-3	NGfmVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnH4NVAh\|ryP	MkjNO\|IhcA>?	NVrRUXM2TE2VTx?=	Mk\ITWM2OD1zMDFOwG0>	NFTs[lczOzh2NECzPC=>
OVCAR-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXVNVAh\|ryP	NWjIXVJ7PzJiaB?=	NVPUT2pHTE2VTx?=	MV3JR\|UxRTFyIN88US=>	Mnu2NlM5PDRyM{i=
OVCAR-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnlVIcyOCEQvF2=	NVHTUJl2PzJiaB?=	MUDEUXNQ	M4HRXWlEPTB;MUCg{txO	MnjZNlM5PDRyM{i=
P3HR-1	NHH4VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOxNEDPxE1?	NF2wS444OiCq	MVfEUXNQ	MU\JR\|UxRTFyIN88US=>	NH3zZpIzOzh2NECzPC=>
PC-3	NHO1O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TVOFExKM7:TR?=	M1j6WFczKGh?	M4[5OmROW09?	MmP4TWM2OD1zMDFOwG0>	M3zlZ\|I{QDR2MEO4
Raji	NVvRWXpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPkW4V3OTBizszN	NFLwPIo4OiCq	NWHJ[FN5TE2VTx?=	MV3JR\|UxRTFyIN88US=>	M1vWWFI{QDR2MEO4
RD	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\WNVAh\|ryP	NVn6[ItHPzJiaB?=	NV3VWVdKTE2VTx?=	MX;JR\|UxRTFyIN88US=>	MlG0NlM5PDRyM{i=
RD-ES	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv2NVAh\|ryP	NIftbnM4OiCq	NHfUTIhFVVOR	MULJR\|UxRTFyIN88US=>	NE[zR2gzOzh2NECzPC=>
RL	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIG5cHcyOCEQvF2=	NXLLVoVEPzJiaB?=	MoCwSG1UVw>?	MX\JR\|UxRTFyIN88US=>	NFzOWmozOzh2NECzPC=>
SaOS2	MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nJbFExKM7:TR?=	NV\k[ZA5PzJiaB?=	MXrEUXNQ	M2[y[WlEPTB;MUCg{txO	M3exVFI{QDR2MEO4
SCC-9	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlSzNVAh\|ryP	NH;k[5E4OiCq	MmLDSG1UVw>?	NEDQfVFKSzVyPUGwJO69VQ>?	MYWyN\|g1PDB\|OB?=
SCC-12	NIDxT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7EbYF6OTBizszN	NUTPTY1wPzJiaB?=	M3n6dWROW09?	NHOx[nVKSzVyPUGwJO69VQ>?	MXuyN\|g1PDB\|OB?=
SCC-13	M{HiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFL4V3gyOCEQvF2=	MWG3NkBp	NGrHcmdFVVOR	NHTQ[XlKSzVyPUGwJO69VQ>?	MXKyN\|g1PDB\|OB?=
SCC-15	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUOxNEDPxE1?	NEjR[Gc4OiCq	Mlu0SG1UVw>?	MoDaTWM2OD1zMDFOwG0>	NGrQOZQzOzh2NECzPC=>
SCC-25	M{nreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXm3XVV[OTBizszN	M2iyR\|czKGh?	MnTWSG1UVw>?	NIrKT25KSzVyPUGwJO69VQ>?	M1zLZlI{QDR2MEO4
SCLC-3	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXUNVAh\|ryP	NFnWVFk4OiCq	MkjlSG1UVw>?	M4nrVWlEPTB;MUCg{txO	M3\lZ\|I{QDR2MEO4
SF-268	NFTKRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xNEDPxE1?	M3TV[lczKGh?	M3Hl[GROW09?	MUjJR\|UxRTFyIN88US=>	NULYT4wyOjN6NESwN\|g>
SF-295	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjzNVAh\|ryP	NH:wfIs4OiCq	MYrEUXNQ	MmWxTWM2OD1zMDFOwG0>	NGXYdoMzOzh2NECzPC=>
SJRH30	NUna[nNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XYblExKM7:TR?=	NFTTPWU4OiCq	MmDVSG1UVw>?	NFrIRoNKSzVyPUGwJO69VQ>?	NGDoXoczOzh2NECzPC=>
SK-BR-3	M1ja[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLVNVAh\|ryP	MnXMO\|IhcA>?	NIjHSINFVVOR	M1PkcWlEPTB;MUCg{txO	MnHmNlM5PDRyM{i=
SK-LMS-1	M1;5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnLPYEyOCEQvF2=	NFP1bJo4OiCq	NFTmNZlFVVOR	NG\pVJNKSzVyPUGwJO69VQ>?	NYm0OHl[OjN6NESwN\|g>
SK-N-DZ	M1HYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVO0ZW16OTBizszN	NVn3RWw6PzJiaB?=	NFfLbmVFVVOR	NVnEenc3UUN3ME2xNEDPxE1?	M{D5dVI{QDR2MEO4
SK-N-F1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxNEDPxE1?	MUK3NkBp	MV\EUXNQ	MmX4TWM2OD1zMDFOwG0>	M2LvcFI{QDR2MEO4
SKOV-3	M4HGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX6xNEDPxE1?	MVm3NkBp	M1\6d2ROW09?	M4rvbGlEPTB;MUCg{txO	MWCyN\|g1PDB\|OB?=
SK-UT-1	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTBNVAyOCEQvF2=	Mkf0O\|IhcA>?	MnnKSG1UVw>?	MX;JR\|UxRTFyIN88US=>	NG[xU3gzOzh2NECzPC=>
SN12C	NX\oZY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj4TY0yOCEQvF2=	NFn3Z\|I4OiCq	M4jtNGROW09?	MmSwTWM2OD1zMDFOwG0>	NH7nZVczOzh2NECzPC=>
SNB-19	NEi4ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYm5OGY6OTBizszN	NWf6[GNJPzJiaB?=	M4TwcWROW09?	MlGwTWM2OD1zMDFOwG0>	MmfYNlM5PDRyM{i=
SNU-5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEns[ogyOCEQvF2=	NGHqd3E4OiCq	NF:0[HZFVVOR	NVfGc3g2UUN3ME2xNEDPxE1?	MoT1NlM5PDRyM{i=
SNU-16	NXvwOo1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHXRoYyOCEQvF2=	NVjiXllxPzJiaB?=	NGrRZ2ZFVVOR	NGnIPXRKSzVyPUGwJO69VQ>?	NUjkN4IxOjN6NESwN\|g>
SNU-398	NVTyfGJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\SPJkyOCEQvF2=	M163dVczKGh?	Mn\sSG1UVw>?	NVqyXYFtUUN3ME2xNEDPxE1?	M4DQU\|I{QDR2MEO4
SNU-449	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxNEDPxE1?	NX3uc49iPzJiaB?=	NHzCTodFVVOR	MoHpTWM2OD1zMDFOwG0>	NFX0TGIzOzh2NECzPC=>
SR	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmxNEDPxE1?	M1rUVFczKGh?	NUm3TW44TE2VTx?=	M1HEcGlEPTB;MUCg{txO	NIToNoIzOzh2NECzPC=>
ST486	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\1XZdmOTBizszN	MW[3NkBp	MoTDSG1UVw>?	MYHJR\|UxRTFyIN88US=>	M1PQWVI{QDR2MEO4
SW579	M4jObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX:xNEDPxE1?	NYLwV\|dRPzJiaB?=	NWrxfYJ7TE2VTx?=	NYfVfVR4UUN3ME2xNEDPxE1?	NGO5cHozOzh2NECzPC=>
SW684	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfrbI57OTBizszN	M2PBdVczKGh?	Mo\KSG1UVw>?	MX\JR\|UxRTFyIN88US=>	NXXuWlQ5OjN6NESwN\|g>
SW-780	M3nyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3L0blExKM7:TR?=	NE\ST4o4OiCq	MknXSG1UVw>?	NF;X[Y1KSzVyPUGwJO69VQ>?	NELTXogzOzh2NECzPC=>
SW900	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fBc\|ExKM7:TR?=	NYnJNIFqPzJiaB?=	M4LubmROW09?	NH\CUlVKSzVyPUGwJO69VQ>?	M2DwWlI{QDR2MEO4
SW1088	NHezd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XFRlExKM7:TR?=	M{LVNlczKGh?	MnTuSG1UVw>?	Mnz1TWM2OD1zMDFOwG0>	Ml[3NlM5PDRyM{i=
SW1463	NIPVVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuxNEDPxE1?	MnK2O\|IhcA>?	NVX0ZpZRTE2VTx?=	NYfQbWlEUUN3ME2xNEDPxE1?	MXOyN\|g1PDB\|OB?=
SW1990	NHrwe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HLblExKM7:TR?=	NH[1W5A4OiCq	Ml\RSG1UVw>?	NY\HOW51UUN3ME2xNEDPxE1?	MVqyN\|g1PDB\|OB?=
T47D	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV2wS3BQOTBizszN	MX23NkBp	MVjEUXNQ	NE\vO\|ZKSzVyPUGwJO69VQ>?	NHHOcJozOzh2NECzPC=>
TE381.T	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;6NVExKM7:TR?=	M4PQW\|czKGh?	NF;zeIRFVVOR	NFSzeGJKSzVyPUGwJO69VQ>?	MoHTNlM5PDRyM{i=
TK-10	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTw[GFkOTBizszN	M3zzcVczKGh?	MmrZSG1UVw>?	NG\mTHNKSzVyPUGwJO69VQ>?	M2jZXFI{QDR2MEO4
U2OS	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3NfpMyOTBizszN	NHL0NHk4OiCq	NVfIO2pqTE2VTx?=	NH;KPYxKSzVyPUGwJO69VQ>?	MW[yN\|g1PDB\|OB?=
U251	NUXXSmF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjGXmhiOTBizszN	MoH3O\|IhcA>?	M3vQVWROW09?	MmLvTWM2OD1zMDFOwG0>	NU[1cJZ{OjN6NESwN\|g>
UACC-812	NWnleWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPtc5pNOTBizszN	Mn3mO\|IhcA>?	MnTPSG1UVw>?	NWDuOGxCUUN3ME2xNEDPxE1?	MX2yN\|g1PDB\|OB?=
YAPC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm0bJc4OTBizszN	MknNO\|IhcA>?	M4PGU2ROW09?	NH34VmlKSzVyPUGwJO69VQ>?	NYHxSoVWOjN6NESwN\|g>
ZR-75-1	NH\kT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LPcFExKM7:TR?=	NUXUNllsPzJiaB?=	NV\PcndzTE2VTx?=	M2fWfmlEPTB;MUCg{txO	MUOyN\|g1PDB\|OB?=
A375	MkHISpVv[3Srb36gZZN{[Xl?	NV\uRZJ5OS5{IN88US=>	MorhOEBp	M2fnWmROW09?	NHix[ZFKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?=	NGHKXVgzOjN6OUS3NS=>
YUSIT1	NFWweIlHfW6ldHnvckBie3OjeR?=			MYnEUXNQ	MWjy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0>	MlL4NlI{QDl2N{G=
MeWo	MkT1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MWLEUXNQ	MV;JR\|UxKD1iOUi3JI5O	MWWyOlAyQDV{NB?=
WiDr	NELOVWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NGXoVoNFVVOR	MnzFTWM2OCB;IEe2JI5O	NEPEOVEzPjBzOEWyOC=>
Colo-205	NG\xb2VHfW6ldHnvckBie3OjeR?=	M{jJeVEh\|ryP	MoixOEBl	NETR[o5FVVOR	NEfUfWdKdmS3Y3XkJIEhcGmpaHz5JINwdXCjcnHicIUh[2:vcHHjeIlwdiCyaHXuc5R6eGV?	NUXJbFQ5OjV\|OEGxOVI>
RBW-1	M1;lZmZ2dmO2aX;uJIF{e2G7	NVizTGVEOSEQvF2=		M4X5OmROW09?	NE[xWJdPdyC{ZXT1Z5Rqd25ib3[gUYVsKDFxMjDwbI9{eGixconsZZRqd25?	MYmyOFg5PTZ7MB?=
RBO-1	MUTGeY5kfGmxbjDhd5NigQ>?	NULFPZVrOSEQvF2=		NILER4pFVVOR	NW[0NnpuUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NW\Je4Z5OjR6OEW2PVA>
RBO-2	Ml:wSpVv[3Srb36gZZN{[Xl?	NGPFRXEyKM7:TR?=		Mn7PSG1UVw>?	M12yeGlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	NIrkOmUzPDh6NU[5NC=>
RBOW	M4H6NWZ2dmO2aX;uJIF{e2G7	MXqxJO69VQ>?		MljMSG1UVw>?	M37wSGlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	MXKyOFg5PTZ7MB?=
M257	NHXON2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XNT\|ExOCCwTR?=	MoXuO\|IhcA>?		M2TSbWRw\XNibn;0JIlvcGmkaYSgdJJwdGmoZYLheIlwdiCxZjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	NH7SVWozOzNzN{S0Oi=>
LCP	NHe0XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLKS\|FxOTByIH7N	M4XXflczKGh?		M1S2PGlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCOQ2CgZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMGKgcZV1[W62YYTpc44>	MlvyNlM{OTd2NE[=
WM266	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jicFExOCCwTR?=	MVK3NkBp		M4HWeGlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>?	Ml7nNlM{OTd2NE[=
M257	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnQNVAxKG6P	M4PybVczKGh?		MlXISI9meyCwb4SgbY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI	NUHKNGpGOjN\|MUe0OFY>
LCP	NFrw[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{i1Z\|ExOCCwTR?=	NF35Sog4OiCq		NGOyTIJKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUGNRKGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBTKG23dHHueIF1cW:w	MXOyN\|MyPzR2Nh?=
WM266	NWfWXmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDpNVAxKG6P	NGrCSm44OiCq		M2\vfGlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDXUVI3PiClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxTCCvdYThcpRifGmxbh?=	NF7xe5IzOzNzN{S0Oi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523, VRT752271) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 135 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 135 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)